Focus  by Friedman, Scott L.
FocusFocus
Scott L. Friedman⇑
Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, United States
See Article, pages 110–117We’ve hit the Iceberg – The threat of NASH-related HCC arrives
During the 12 years since the risk of hepatocellular carcinoma
(HCC) ﬁrst surfaced in patients with fatty liver disease and ‘cryp-
togenic’ cirrhosis, we have likened this rising incidence to ‘the tip
of an iceberg’. A rigorous epidemiologic study from Newcastle in
the United Kingdom by Dyson et al. in this month’s issue of the
Journal convincingly demonstrates that we have now struck the
iceberg itself – non-alcoholic steatohepatitis (NASH) is a domi-
nant cause of HCC.
Reports linking NASH to HCC ﬁrst began to appear in 2001 in
Japan, the US and Europe [1–3]. Concurrently, studies highlighted
the generalized risk of cancer – including HCC – among patients
who are overweight or obese [4]. Many of the HCCs in these ini-
tial reports arose in patients with ‘cryptogenic’ cirrhosis, who
bore historical or metabolic vestiges of metabolic syndrome but
no longer had classic biopsy features of NASH, leading to the
moniker of ‘burnt-out NASH’ for such individuals. More worri-
some has been the recent increase of HCC in patients with NASH
who do not yet have cirrhosis [5,6], raising uncertainty about the
optimal screening strategy for early detection of HCC, which is
essential to preserve the hope of curative therapies that include
ablation, resection or transplantation.
The Dyson study carefully characterizes the demographics of
HCC from 2000 to 2010 in the region surrounding Newcastle-
upon-Tyne in North East England. The effort beneﬁted from a
well-maintained regional cancer registry created by the National
Health Service, and the formation of regional specialist ‘multidis-
ciplinary meetings’ (MDM) to centralize care of complex diseases
at centers of excellence, thereby ensuring that most patients
(>75%) within the region were captured and received specialized
care. During this interval, the regional mortality, which reﬂected
the overall incidence of HCC rose 1.8 fold, mirroring trends in
other epidemiologic studies of HCC. Not surprisingly, this rising
incidence of HCC has been associated with a staggering preva-
lence in England of overweight, obesity or morbid obesity rising
from 61% in 2000 of 65.5% in 2010.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.Most striking in the Dyson data was a >10 fold increase in HCC
associated with NAFLD, accounting for 34.8% of all the cases in
2010, and making it the single most common underlying etiology.
Case deﬁnitions for NAFLD were quite stringent, and required
absence of other etiologies including alcohol, combined with evi-
dence of fatty liver disease on biopsy or imaging. As in previous
reports,HCCwasdetected in the absenceof cirrhosis in somecases,
but these patients now comprised 30% of the HCCs diagnosed,
which reﬂects a very worrisome trend. Patients with NAFLD-
associated HCC (with or without cirrhosis) were older than those
with other etiologies and less likely to be detected by surveillance,
yet their overall survival was the same, which was attributed
in part to the lower prevalence of cirrhosis and advanced liver
disease and a higher likelihood of incidental detection.
The rising incidence of HCC in the absence of cirrhosis in
NAFLD obligates us to seek mechanisms of carcinogenesis that
are related to the pathogenesis of the underlying disease rather
than to ﬁbrosis alone. Initial reports further indicate that at least
some HCCs arising in non-cirrhotic NASH have distinct histologic
features [7,8]. While the picture is far from complete, animal
models and other preclinical studies have borne remarkable pro-
gress in uncovering potential carcinogenic pathways directly
related to NASH. Several candidate mechanisms have emerged,
including altered nuclear receptor signaling (FXR, PPARa, and
vitamin D receptor), dysbiosis from a perturbed microbiome
and gut-liver axis, disturbed bile salt homeostasis, an altered
microenvironment due to interactions between activated stellate
cells and liver macrophages, and increased progenitor cell
responses that could underlie stem cell-driven cancers.
An altered intestinal microbiome is now implicated in the
development of obesity, insulin resistance and NAFLD by enhanc-
ing caloric extraction from the diet and altering the bioavailabil-
ity of essential nutrients such as choline [9]. At the same time
bacterial overgrowth may compromise gut barrier integrity and
lead to activation of the inﬂammasome in hepatocytes, an intra-
cellular protein scaffold, to enhance cellular injury and chronic
inﬂammation driven by the innate immune response. Two ele-
gant studies have now drawn stellate cells into this microbiom-
e-driven inﬂammatory axis, by focusing on the contribution of
the senescence associated secretory phenotype (SASP) in these
cells. An altered gut microbiome associated with a high fat diet
in mice leads to increased levels of deoxycholic acid, which accel-
erates SASP in stellate cells via the enterohepatic circulation;
these ﬁndings have been identiﬁed in human NASH as well14 vol. 60 j 1–2
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[10]. In a separate study, loss of p53-dependent SASP leads to
altered macrophage polarization in the liver’s microenvironment,
favoring the predominance of M1 macrophages, which are gener-
ally tumor promoting [11]. Loss of p53 in stellate cells, while not
yet documented in human liver, could therefore amplify a tumor-
permissive microenvironment [11].
Three nuclear receptors FXR, PPARa, and vitamin D receptor,
and their cognate ligands are protective against HCC and may
be suppressed as fatty liver disease progresses (reviewed in
[12]). Other receptors also implicated in protection from HCC
include PXR, CAR and the G protein coupled receptor Tgr5.
NAFLD and NASH have been associated with a brisk progeni-
tor cell response, which has been attributed in part to enhanced
hedgehog signaling in regions of injury [13]. Hedgehog (Hh) acti-
vation has been implicated in tumor stroma crosstalk in other
tumor models [14] and could represent a potential therapeutic
target because a Hh antagonist is already in use to treat basal cell
carcinoma.
In returning the clinical implications of the Dyson study, it
remains to be determined whether the risk of HCC will parallel
the rising incidence of NAFLD to the same extent in all ethnic-
ities, since this study population was 97% Caucasian. Speciﬁ-
cally, will genetic determinants of NAFLD that are more
common in other ethnicities, for example a PNPLA3 polymor-
phism in Latinos [15], independently increase HCC risk, and
will this necessitate targeted screening strategies for patients
at high risk? Moreover, should the presence of signiﬁcant ste-
atosis in chronic liver disease from other etiologies also
heighten screening since it still increases the risk of HCC?
Regardless of the answers to these questions, with 30% of the
HCCs arising in non-cirrhotic livers of patients with NAFLD in
the Dyson study, a thorough reassessment of current screening
strategies is warranted, because if we wait until cirrhosis is
present to begin screening in NAFLD it will be too late for
many patients.
Both the authors of the Dyson study and the National Health
Service should be commended for implementing and executing a
disciplined system of disease tracking and centralization of care.
In addition to facilitating the detection of an important epidemi-
ologic trend, their efforts have reinforced the value of focusing
expertise in regional centers to ensure that care and outcomes
are optimized. This strategy is not only rational, but is likely to
reduce costs and improve efﬁciencies [16].
To use a trite metaphor, just as the Titanic sailed from the
United Kingdom only to encounter an iceberg, Dyson and
colleagues from Newcastle have come upon an iceberg that is
far more pervasive, and threatens even greater hardship than
the cold North Atlantic did in 1912.2 Journal of Hepatology 2Conﬂict of interest
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